Premium
Sub‐optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro‐oesophageal reflux disease
Author(s) -
GUNARATNAM N. T.,
JESSUP T. P.,
INADOMI J.,
LASCEWSKI D. P.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02911.x
Subject(s) - dosing , bedtime , proton pump inhibitor , medicine , reflux , gastro , population , proton pump , gastroenterology , disease , pharmacology , biology , biochemistry , environmental health , atpase , enzyme
Summary Background Proton pump inhibitors are the most potent drug treatment for gastro‐oesophageal reflux disease. Premeal dosing maximizes efficacy while sub‐optimal dose timing may limit efficacy. Aim To determine the prevalence of sub‐optimal proton pump inhibitor dosing in a community‐based gastro‐oesophageal reflux disease population. Materials and methods One hundred patients on proton pump inhibitors referred for persistent gastro‐oesophageal reflux disease symptoms were questioned about their proton pump inhibitor dosing habits and classified as optimal or sub‐optimal dosers. Optimal dosers took proton pump inhibitors with or up to 60 min before meals. Sub‐optimal dosers took proton pump inhibitors >60 min before meals, after meals, as needed, or at bedtime. Results Forty‐six percent dosed optimally. Fifty‐four percent dosed sub‐optimally with 21 of 54 (39%) dosing >60 min before meals, 16 (30%) after meals, 15 (28%) at bedtime and two (4%) as needed. Only 6% of the subjects on once‐daily proton pump inhibitor regimens and 33% of subjects taking proton pump inhibitors two‐ to three times daily dosed in a manner that maximized acid suppression (15–30 min before a meal). Conclusions In this study, 54% of patients dosed proton pump inhibitors sub‐optimally and only 12% dosed in a manner that maximized acid suppression. As sub‐optimal proton pump inhibitor dose timing can limit efficacy, patients with refractory symptoms should be asked about dose timing to avoid inappropriate and costly dose escalations.